5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials

Leukemia and Lymphoma

Volumn 53, Issue 8, 2012, Pages 1558-1560

  Breccia, Massimo ^a   Loglisci, Giuseppina ^a   Salaroli, Adriano ^a   Serrao, Alessandra ^a   Petrucci, Luigi ^a   Mancini, Marco ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

azacitidine; elderly; Myelodysplastic syndromes; outcome; safety

Indexed keywords

AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA TYPE 2; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; REFRACTORY ANEMIA WITH EXCESS OF BLASTS TYPE 1; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; AZACITIDINE; COHORT STUDIES; CYTOGENETICS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84864248084     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.660632     Document Type: Article

References (7)

1. Silverman LR, Demakos EP, Peterson BL, et al. Randomized, controlled trial of azacitidine in patients with the myelodysplasticsyndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20:2429-2440.
2. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al.; International Vidaza High-Risk MDS Survival Study Group. Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open label,phase III study. Lancet Oncol 2009;10:223-232.
3. Itzkynson R, Th epot S, Quesnel B, et al.; Groupe Francophone des Myelodysplasies (GFM). Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403-411.
4. Vardiman JW, Th iele J, Arber DA, et al. Th e 2008 revision of the World Health Organization (WHO) classifi cation of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114: 937-951.
5. C heson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modifi cation of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-425.
6. Campelo MD, Delgado RG, Godoy Molias AC, et al. Azacitidine for the treatment of myelodysplastic syndromes in the elderly. Adv Th er 2011;28:10-15.
7. S eymour JF, Fenaux P, Silverman LR, et al. Eff ects of azacitidine compared with conventional care regimens in elderly (- 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev OncolHematol 2010;76:218-227.